Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Short term Debt: 2021-2025

Historic Short term Debt for Harmony Biosciences Holdings (HRMY) over the last 4 years, with Sep 2025 value amounting to $20.0 million.

  • Harmony Biosciences Holdings' Short term Debt rose 33.33% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 33.33%. This contributed to the annual value of $16.2 million for FY2024, which is 8.33% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Short term Debt stood at $20.0 million for Q3 2025, which was up 6.67% from $18.8 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Short term Debt's 5-year high stood at $20.0 million during Q3 2025, with a 5-year trough of $2.0 million in Q3 2021.
  • In the last 3 years, Harmony Biosciences Holdings' Short term Debt had a median value of $15.0 million in 2024 and averaged $15.0 million.
  • Data for Harmony Biosciences Holdings' Short term Debt shows a peak YoY skyrocketed of 650.00% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Short term Debt stood at $2.0 million in 2021, then remained steady at $2.0 million in 2022, then soared by 650.00% to $15.0 million in 2023, then rose by 8.33% to $16.2 million in 2024, then surged by 33.33% to $20.0 million in 2025.
  • Its last three reported values are $20.0 million in Q3 2025, $18.8 million for Q2 2025, and $17.5 million during Q1 2025.